Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.
Epistemonikos ID: c875b9483c81a1b2b5ceff4652d924fc0fb3a6af
First added on: Jun 26, 2025